| 长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究 |
| 投稿时间：2012-08-15 修订日期：2012-10-29 点此下载全文 |
| 引用本文：何志高,严俊,陈国涵,鲍思蔚,翟晓波,金丽,施燕.长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究[J].药学实践杂志,2012,30(6):462~463,480 |
| 摘要点击次数: 2601 |
| 全文下载次数: 988 |
|
| 基金项目:浦东新区卫生系统医学领先人才培养项目(PWRd2007-12)资助. |
|
| 中文摘要:目的 评价长春瑞滨(NP)或吉西他滨GP)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和成本效用。方法 60例晚期NSCLC患者,每组30例,化疗4周期后,评价疗效和成本效用。结果 NP组和GP组治疗的有效率分别为36.6%和40.0%,中位生存期分别为8.52和8.37月,统计学检验发现两者之间的差异无统计学意义,P>0.05。NP组和GP组治疗的一年生存率分别为36.6%和33.3%;2年生存率分别为16.6%和13.3%,成本效用比分别为1 123.41和1 556.61。结论 NP和GP方案治疗NSCLC疗效基本相似,但NP方案治疗的成本效用相对较好。 |
| 中文关键词:长春瑞滨 吉西他滨 顺铂 晚期非小细胞肺癌 化疗 成本效用分析 |
| |
| Cost utility analysis of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer |
|
|
| Abstract:Objective To compare and evaluate the effectiveness and cost utility of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer. Methods 60 advanced patients wit NSCLC were enrolled into two groups, the effectiveness and cost utility were evaluated after 2 cycles.Results The efficacy rate wit NP and GP were 36.6%and 40.0% respectively, An existence period wit NP and GP were 8.52 and 8.37 respectively, showing no significant difference (P>0.05) between the two groups. One year survival rate with NP and GP were 36.6%and 40.0% respectively; two year survival rate with NP and GP were 16.6%and 13.3% respectively. The ratio of cost utility with NP and GP were 1123.41and 1556.61 respectively. Conclusion The effectiveness of NP versus GP of advanced non-small cell lung cancer was similar, the cost utility of NP was more than GP. |
| keywords:vinorelbine gemcitabine cisplatin advanced non-small cell lung cancer chemotherapy cost utility analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
